Literature DB >> 30041730

Clearance Concepts: Fundamentals and Application to Pharmacokinetic Behavior of Drugs.

Reza Mehvar1.   

Abstract

Clearance concepts were introduced into the pharmacokinetics discipline in the 1970s and since then have played a major role in characterization of the pharmacokinetic behavior of drugs. These concepts are based on the relationship between organ extraction ratio or clearance and physiologic parameters such as the organ blood flow and the intrinsic capability of the eliminating organ to remove the free (unbound) drug from the body. Several theoretical models have been developed, which define these relationships and may be used to predict the effects of changes in the physiological parameters on various pharmacokinetic parameters of drugs, such as drug clearance. In this communication, the fundamentals of the two most widely used models of hepatic metabolism, namely the well-stirred (venous equilibrium) and parallel-tube (sinusoidal perfusion) models, are reviewed. Additionally, the assumptions inherent to these models and the differences between them in terms of their predictive behavior are discussed. The effects of changes in the physiologic determinants of clearance on the blood concentration-time profiles of drugs with low and high extraction ratio are also presented using numerical examples. Lastly, interesting and unusual examples from the literature are provided where these concepts have been applied beyond their widely known applications. These examples include estimation of the oral bioavailability of drugs in the absence of otherwise needed intravenous data, differentiation between the role of liver and gut in the first-pass loss of drugs, and distinction between the incomplete absorption and first-pass metabolism in the gastrointestinal tract after the oral administration of drugs. It is concluded that the clearance concepts are a powerful tool in explaining the pharmacokinetics of drugs and predicting the changes in their blood concentration-time courses when the underlying physiologic parameters are altered due to age, disease states, or drug interactions.    This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30041730     DOI: 10.18433/jpps29896

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  4 in total

1.  Prediction of hepatic drug clearance with a human microfluidic four-cell liver acinus microphysiology system.

Authors:  Courtney Sakolish; Yu-Syuan Luo; Alan Valdiviezo; Lawrence A Vernetti; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicology       Date:  2021-09-17       Impact factor: 4.221

2.  Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.

Authors:  Kamunkhwala Gausi; Lubbe Wiesner; Jennifer Norman; Carole L Wallis; Carolyne Onyango-Makumbi; Tsungai Chipato; David W Haas; Renee Browning; Nahida Chakhtoura; Grace Montepiedra; Lisa Aaron; Katie McCarthy; Sarah Bradford; Tichaona Vhembo; Lynda Stranix-Chibanda; Gaerolwe R Masheto; Avy Violari; Blandina T Mmbaga; Linda Aurpibul; Ramesh Bhosale; Neetal Nevrekhar; Vanessa Rouzier; Enid Kabugho; Mercy Mutambanengwe; Vongai Chanaiwa; Mandisa Nyati; Tsungai Mhembere; Fuanglada Tongprasert; Anneke Hesseling; Katherine Shin; Bonnie Zimmer; Diane Costello; Patrick Jean-Philippe; Timothy R Sterling; Gerhard Theron; Adriana Weinberg; Amita Gupta; Paolo Denti
Journal:  Clin Pharmacol Ther       Date:  2020-10-16       Impact factor: 6.875

3.  CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry.

Authors:  Espen Molden; Marin M Jukić
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

4.  Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine.

Authors:  Tanja M Gampfer; Lea Wagmann; Yu Mi Park; Annelies Cannaert; Jennifer Herrmann; Svenja Fischmann; Folker Westphal; Rolf Müller; Christophe P Stove; Markus R Meyer
Journal:  Arch Toxicol       Date:  2020-04-05       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.